Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation

Garderet, Laurent; Bittencourt, Henrique; Kaliski, Alexandre; Daniel, Marie‐Thérèse; Ribaud, Patricia; Socié, Gérard; Gluckman, Éliane

doi:10.1034/j.1600-0609.2001.00377.x

Cited by 25 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The course of the disease is aggressive, with a median survival of usually less than 1 year [2]. The disease is often refractory to conventional chemotherapy (eg., alkylating agents or CHOP regimens), and it is considered incurable [2]. …”

Section: Discussionmentioning

confidence: 99%

“…Garderet et al reported that all cases with CNS involvement of PLL are of B cell origin; they have not been found to be associated with T-PLL. T-PLL of CNS is treated with non-myeloablative allogeneic stem cell transplantation [2]. Non-invasive diagnostic imaging techniques are usually inadequate for diagnosis.…”

Section: Discussionmentioning

confidence: 99%

“…Symptomatic central nervous system involvement (CNS) is a rare complication in T-cell prolymphocytic leukemia (T-PLL), although it is common in acute leukemia and non-Hodgkin’s lymphoma [1,2,3,4,5]. We report a case of T-PLL with symptomatic infiltration of the brain that was histopathologically proven with stereotactic brain biopsy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Central Nervous System Involvement of T-cell Prolymphocytic Leukemia Diagnosed with Stereotactic Brain Biopsy: Case Report

Göçmen¹,

Kutlay²,

Erikçi³

et al. 2014

Tjh

View full text Add to dashboard Cite

Prolymphocytic leukemia (PLL) is a generalized malignancy of the lymphoid tissue characterized by the accumulation of monoclonal lymphocytes, usually of B cell type. Involvement of the central nervous system (CNS) is an extremely rare complication of T-cell prolymphocytic leukemia (T-PLL). We describe a case of T-PLL presenting with symptomatic infiltration of the brain that was histopathologically proven by stereotactic brain biopsy. We emphasize the importance of rapid diagnosis and immediate treatment for patients presenting with CNS involvement and a history of leukemia or lymphoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Central Nervous System Involvement of T-cell Prolymphocytic Leukemia Diagnosed with Stereotactic Brain Biopsy: Case Report

Göçmen¹,

Kutlay²,

Erikçi³

et al. 2014

Tjh

View full text Add to dashboard Cite

show abstract

“…Allogeneic stem cell transplantation is currently the only available potential curative option for T-PLL. Recommendation for consolidative stem cell transplant is primarily made from case reports and retrospective studies (11)(12)(13)(18)(19)(20)(21).…”

Section: Role Of Hematopoietic Stem Cell Transplantmentioning

confidence: 99%

Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia

Varadarajan

Ballen

2022

Front. Oncol.

View full text Add to dashboard Cite

T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive hematologic malignancy with a poor prognosis. Alemtuzumab (Campath) remains the cornerstone for treatment, with an 80% complete response (CR). Hematopoietic stem cell transplant (HSCT) is considered the standard of care as consolidative therapy in eligible patients. However, allogeneic stem cell transplant is also complicated by increased rates of infections from chemotherapy, acute graft-versus-host disease (GVHD), and chronic GVHD. This review aims to report the available literature on the efficacy and complications of consolidative HSCT. It also discusses the importance of patient selection and pre- and post-transplant complications including atypical infections and GVHD.

show abstract

“…It offers a relatively high response rate of 50–100%, but these responses are not durable, and the majority of patients will relapse within 1–2 years without additional therapy. Stem cell transplantation (SCT) in carefully selected patients appears to offer long-term remission [39,40,41,42,43,44,45,46]. A multicenter retrospective study suggested that SCT after alemtuzumab may provide more benefit than alemtuzumab therapy alone.…”

Section: Review Of Literaturementioning

confidence: 99%

A Case Report of T Cell Prolymphocytic Leukemia and Kaposi Sarcoma and a Review of T Cell Prolymphocytic Leukemia

Paul¹,

Alizadeh

Ajayi³

et al. 2012

Acta Haematol

View full text Add to dashboard Cite

T cell prolymphocytic leukemia (T-PLL) is a rare mature T cell lymphoproliferative disease. It has been associated with an aggressive course, a poor response to conventional chemotherapy and a short median survival. Here we present a rare case of concurrent T-PLL and Kaposi sarcoma who achieved a complete hematologic and cytogenetic remission after a very short course of treatment with alemtuzumab. A review of T-PLL was done. In this review, clinical features, laboratory features and current therapeutic strategies of T-PLL are presented.

show abstract

Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation

Abstract: The reasons why treatment may have failed are discussed (nature of disease, disease progression, treatment schedule).

Cited by 25 publications

References 14 publications

Central Nervous System Involvement of T-cell Prolymphocytic Leukemia Diagnosed with Stereotactic Brain Biopsy: Case Report

Central Nervous System Involvement of T-cell Prolymphocytic Leukemia Diagnosed with Stereotactic Brain Biopsy: Case Report

Advances in Cellular Therapy for T-Cell Prolymphocytic Leukemia

A Case Report of T Cell Prolymphocytic Leukemia and Kaposi Sarcoma and a Review of T Cell Prolymphocytic Leukemia

Contact Info

Product

Resources

About